Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers.
暂无分享,去创建一个
M. Ingelman-Sundberg | L. Bertilsson | R. Baldwin | J. Mwinyi | R. Pedersen | R. M. Baldwin | E. Eliasson | Staffan Ohlsson | R. Baldwin | Rasmus Steen Pedersen
[1] H. Refsum,et al. Impact of the Ultrarapid CYP2C19*17 Allele on Serum Concentration of Escitalopram in Psychiatric Patients , 2008, Clinical pharmacology and therapeutics.
[2] Hua Jiang,et al. Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide-based regimens in multiple myeloma , 2007, Haematologica.
[3] S. Penzak,et al. Does Metronidazole Interact with CYP3A Substrates by Inhibiting Their Metabolism Through This Metabolic Pathway? Or Should Other Mechanisms Be Considered? , 2007, The Annals of pharmacotherapy.
[4] M. Hayakari,et al. Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations , 2007, European Journal of Clinical Pharmacology.
[5] T. Starzynska,et al. Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients , 2006, European Journal of Clinical Pharmacology.
[6] R. Hunt,et al. The Effect of CYP2C19 Polymorphisms on H. pylori Eradication Rate in Dual and Triple First-Line PPI Therapies: A Meta-analysis , 2006, The American Journal of Gastroenterology.
[7] U. Klotz. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. , 2006, International journal of clinical pharmacology and therapeutics.
[8] Y. Böttiger. Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4 , 2006, European Journal of Clinical Pharmacology.
[9] Leif Bertilsson,et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants , 2006, Clinical pharmacology and therapeutics.
[10] D. Kwiatkowski,et al. Haplotype block structure of the cytochrome P450 CYP2C gene cluster on chromosome 10 , 2005, Nature Genetics.
[11] A. Munakata,et al. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. , 2005, British journal of clinical pharmacology.
[12] Zeruesenay Desta,et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. , 2004, Arthritis and rheumatism.
[13] U. Klotz,et al. CYP2C19 polymorphism and proton pump inhibitors. , 2004, Basic & clinical pharmacology & toxicology.
[14] J Licinio,et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response , 2004, Molecular Psychiatry.
[15] L. Bertilsson,et al. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. , 2003, British journal of clinical pharmacology.
[16] Hong-Guang Xie,et al. Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects , 1999 .
[17] K. Ohashi,et al. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans , 1999, Clinical pharmacology and therapeutics.
[18] Kyoichi Ohashi,et al. Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer , 1998, Annals of Internal Medicine.
[19] T. Andersson,et al. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. , 1998, British journal of clinical pharmacology.
[20] L. Bertilsson,et al. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects , 1997, Clinical pharmacology and therapeutics.
[21] A. D. Rodrigues,et al. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[22] L. Bertilsson,et al. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. , 1995, Pharmacogenetics.
[23] J. Miners,et al. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. , 1994, British journal of clinical pharmacology.
[24] J. Miners,et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. , 1993, British journal of clinical pharmacology.
[25] K. Brøsen,et al. Pharmacokinetics of Citalopram in Relation to the Sparteine and the Mephenytoin Oxidation Polymorphisms , 1993, Therapeutic drug monitoring.
[26] Kaoru Kobayashi,et al. Simultaneous determination of omeprazole and its metabolites in plasma and urine by reversed-phase high-performance liquid chromatography with an alkaline-resistant polymer-coated C18 column. , 1992, Journal of chromatography.
[27] T. Andersson,et al. The Pharmacokinetics of Omeprazole in Humans—A Study of Single Intravenous and Oral Doses , 1990, Therapeutic drug monitoring.
[28] L. Bertilsson,et al. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype , 1990 .
[29] D. Greenblatt,et al. Metronidazole Impairs Clearance of Phenytoin but Not of Alprazolam or Lorazepam , 1988, Journal of clinical pharmacology.
[30] D. Flockhart,et al. Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.